Masaru Tsukahara, Ryuhei So, Shinichiro Nakajima, Kohei Kitagawa, Masafumi Kodama, Hiroyoshi Takeuchi
International clinical psychopharmacology 2023 Mar 01This retrospective cohort study aimed to investigate the longitudinal changes in clozapine dose over a 5-year period in patients with treatment-resistant schizophrenia (TRS). Patients with TRS who were administered clozapine at a hospital between April 2012 and December 2016 and continued treatment with clozapine for at least 1 year were included. Clozapine doses were compared at the dose-fixation point, defined as when the same regimen of clozapine had been continued for 8 weeks or longer, and the post-dose-fixation phase, at 12, 36 and 60 months after clozapine initiation. We included 103 patients and found no significant differences in clozapine dose between the dose-fixation point and post-dose-fixation phase. Approximately half of the patients were categorized into an unchanged group at 12 months after clozapine initiation, whereas approximately 40% of patients were categorized into either the decreased or increased group at 60 months. Multivariable regression analysis revealed that the change in clozapine dose between the dose-fixation point and 60 months after clozapine initiation was negatively associated with clozapine dose at the dose-fixation point. On average, the clozapine dose was unchanged during long-term treatment in patients with TRS, although the dose was decreased or increased in approximately 40% of the patients. Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Masaru Tsukahara, Ryuhei So, Shinichiro Nakajima, Kohei Kitagawa, Masafumi Kodama, Hiroyoshi Takeuchi. Longitudinal changes in clozapine dose in patients with treatment-resistant schizophrenia: a 5-year retrospective cohort study. International clinical psychopharmacology. 2023 Mar 01;38(2):96-101
PMID: 36165515
View Full Text